Skip to main content

Table 2 Combined efficacy and activity results

From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Outcomes Pts (RCTs) HR/RR (95% CI) p-value Het. (p) AD (%) NNT
PFS       
1st line 2,695 (3) 0.68 (0.56, 0.81) 0.0001 0.0001 8.4 12
2nd line 1,146 (2) 0.86 (0.69, 1.07) 0.19 0.14 - -
OS       
1st line 2,695 (3) 0.95 (0.85, 1.05) 0.338 0.64 - -
2nd line 684 (1) 0.90 (0.71, 1.14) 0.38 1.00 - -
ORR       
1st-line 2,695 (3) 1.46 (1.21, 1.77) < 0.0001 0.008 11.5 8-9
2nd-line 1,146 (2) 1.58 (1.00, 2.52) 0.05 0.092 8.4 12
  1. Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNT: number needed to treat.